Skip to content
Company Analysis

The Oncology Institute, Inc. TOI

A comprehensive view of key metrics, scores, and financial health for The Oncology Institute, Inc.

Overview of The Oncology Institute, Inc.

TOI NCM
Healthcare Medical Care Facilities Framework: General Corporate Small Cap
The Oncology Institute, Inc. (TOI), is a Small Cap company, in the Medical Care Facilities industry, last closed at $5.31, about 22.6% undervalued vs fair value, +115.0% 1Y return, ranked 1043/1122 in sector.
USD 5.31
3.51%
(Delayed)
• Vol 90d: 74.4%
52-Week Range
Market Cap
$467.92M
Enterprise Value
$543.81M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Weak
Completeness: 82%
Confidence: 53%
Updated: Mar 8
Top Beats

Quick Facts

Website https://theoncologyinstitute.c...
HQ Cerritos, CA
Employees 825
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$6
$7
$7
Current: $5.31 +23% vs base

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$393.4M
21.3%%
Gross Profit
$54.0M
-9.4%%
Operating Income
$-60.1M
0.1%%
Net Income
$-64.7M
22.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
46.9%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating The Oncology Institute, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
27
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
27
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing TOI's balance between Growth (53.0%), Profitability (12.5%), and Safety (34.5%). Growth 53% Safety 34% Profitability 13%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

78th percentile vs peers
78
Key Signals
Rev Growth YoY 21.3% 83p Revenue CAGR 3Y 24.7% 85p EPS Growth YoY 23.5% 60p
Strengths
  • Rev Growth YoY in top 20% of peers (21.3%, 83th percentile)
  • Revenue CAGR 3Y in top 20% of peers (24.7%, 85th percentile)
  • D/E Ratio in top 20% of peers (34.31, 99th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Net Debt/EBITDA in top 20% of peers (11.21, 91th percentile)
Risks

No significant risks identified for this axis.

Profitability

18th percentile vs peers
18
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

50th percentile vs peers
51
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for The Oncology Institute, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$6.51
- - -
+22.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000